公开(公告)号：US20220160718A1

公开(公告)日：2022-05-26

申请号：US17581481

申请日：2022-01-21

Applicant: Bristol-Myers Squibb Company

Inventor： Qihong Zhao ,  Joseph Fargnoli ,  Murali Gururajan ,  Susan Wee

IPC: A61K31/53 ,  C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61P35/04 ,  A61K9/00 ,  A61K45/06

Abstract: The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.

公开(公告)号：US20190224205A1

公开(公告)日：2019-07-25

申请号：US16253353

申请日：2019-01-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qihong Zhao ,  Joseph Fargnoli ,  Murali Gururajan ,  Susan Wee

IPC: A61K31/53 ,  A61K9/00 ,  A61K45/06 ,  C07K16/28 ,  A61P35/04

Abstract: The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.